Primera Bioscience Research Inc. Research Update

TORONTO, ONTARIO--(Marketwire - February 19, 2009) - Primera Bioscience Research Inc. (“Primera Bioscience” or the “Corporation”) announces that The Hospital for Sick Children (“HSC”) in Toronto, Ontario, will be presenting a report to the Board on the research completed to date into stem cells in certain brain tumours. This on-going project has been funded by Primera Bioscience since February 2008. A further announcement discussing research progress will be made upon receipt of the report.

At December 31, 2008, Primera Bioscience had a liability of $100,000 to complete its project funding obligation of $300,000. This amount was due and payable on February 8, 2009. HSC has agreed to extend the deadline for this payment pending presentation of the progress report.

Primera Bioscience is engaged in early stage biomedical research. The Corporation currently has one project which is to collaborate with and provide $300,000 of funding for certain brain tumour and stem cell research being conducted by The Hospital for Sick Children in Toronto, Ontario. This research is more fully described in the prospectus of Primera Bioscience dated July 23, 2008 which is filed on www.sedar.com.

WARNING: This News Release includes certain “forward-looking statements”. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding research and the potential results thereof, and future plans and objectives of Primera Bioscience, are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Primera Bioscience’s expectations are exploration risks detailed herein and from time to time in the filings made by Primera Bioscience with securities regulators.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.